What was the sales growth rate for the company's oncology portfolio before the lockdowns 
iete Generale -- Analyst
Vas, a quick one on China, please. As China is a key country for you. Could you please elaborate on the dynamic there for your key products and if there is any, let's say, impact from lockdowns. And could you refresh our memories and please remind us the current contribution and your ambition on this country.
Vas Narasimhan -- Chief Executive Officer
Yes. With respect -- thanks, Florent. For China, we've outlined our aspiration to become a top three player by 2024, which would be a player that exceeds $4 billion in sales in the market. We've had really a record performance in terms of number of approvals over recent years.
And then also moving forward, I think we'll lead the industry as well in terms of NRDL listings. Key drivers for us has been our oncology portfolio, Entresto, Cosentyx, Lucentis, among others. Now we were growing in the high teens from a sales growth standpoint before the lockdowns. And I think the lockdown -- we continue to grow, but we're growing more in the high single-digit frame at the moment.
And we would expect that to continue until we would see a shift in the overall ability for patients to access medical care in more normal dynamics. That's part of the reason why you see the slowdown in Cosentyx that we saw. With Entresto, given the strength of our overall performance globally, it doesn't really move the needle on that particular brand. So the key brand where it has an impact is Cosentyx and, to a smaller extent, in some of the other brands.
Nonetheless, we continue to believe, given that there's over 1 billion patients -- 1 billion people we can serve with our portfolio of medicines, we have to continue to find ways to continue to reach patients in the framework that is currently in place. And then also be ready that if there's a further opening up, to continue to expand our growth in the market. And importantly, we believe Leqvio and some of our other medicines, Pluvicto, Leqvio, among others, could be significant medicines in China over time.
Operator
Your next question comes from the line of Andrew Baum from Citi.
Andrew Baum -- Citi -- Analyst
A question on the IRA impact on catastrophic coverage and the burden on PBMs and managed care. A significant part of Kisqali is through the Medicare channel. Ibrance seems to be available at a much lower price post genericization. To what extent -- to what extent, excuse me, do you see deflation of the price of Kisqali within the Medicare segment because there'll be preauthorization step [Inaudible] within Medicare prior to gaining access to Kisqali? And do you see any risk of spillover of that, assuming that thesis is correct, to the commercial book of business?
Vas Narasimhan -- Chief Executive Officer
That's a good question, Andrew. I think in general I'd say we're doing a lot of scenario planning on how the IRA could impact various brands. And I think certainly on our minds is how the increased exposure of PBMs in the catastrophic, how that will get transferred or translated into actions against some of our medicines. I think the key for us to differentiate versus a generic in a class like in the CDK4/6, will be having a broader indication -- set of indications relative to the existing medicine.
So I think that's going to be absolutely critical for us in this class to hopefully have the opportunity to expand into, as I mentioned earlier, Stage 2a, Stage 2b, and Stage 3 patients. Otherwise, I think there could certainly be spillover from -- in the metastatic setting if there aren't broad indications for the other 2 players. So we'll have to see how this plays out. I would also say, in general, in some of these cancer classes, such as the CDK4/6, you do see contracting and you do see the opportunity for commercial insurers to get rebates from branded products.
So that would be the, I think, tension there in the system, is they would have to give up their commercial rebates to potentially utilize the generic. So we'll have to see ultimately how all of this plays out. Thank you, Andrew.
Operator
Your next question comes fro
iete Generale -- Analyst
Vas, a quick one on China, please. As China is a key country for you. Could you please elaborate on the dynamic there for your key products and if there is any, let's say, impact from lockdowns. And could you refresh our memories and please remind us the current contribution and your ambition on this country.
Vas Narasimhan -- Chief Executive Officer
Yes. With respect -- thanks, Florent. For China, we've outlined our aspiration to become a top three player by 2024, which would be a player that exceeds $4 billion in sales in the market. We've had really a record performance in terms of number of approvals over recent years.
And then also moving forward, I think we'll lead the industry as well in terms of NRDL listings. Key drivers for us has been our oncology portfolio, Entresto, Cosentyx, Lucentis, among others. Now we were growing in the high teens from a sales growth standpoint before the lockdowns. And I think the lockdown -- we continue to grow, but we're growing more in the high single-digit frame at the moment.
And we would expect that to continue until we would see a shift in the overall ability for patients to access medical care in more normal dynamics. That's part of the reason why you see the slowdown in Cosentyx that we saw. With Entresto, given the strength of our overall performance globally, it doesn't really move the needle on that particular brand. So the key brand where it has an impact is Cosentyx and, to a smaller extent, in some of the other brands.
Nonetheless, we continue to believe, given that there's over 1 billion patients -- 1 billion people we can serve with our portfolio of medicines, we have to continue to find ways to continue to reach patients in the framework that is currently in place. And then also be ready that if there's a further opening up, to continue to expand our growth in the market. And importantly, we believe Leqvio and some of our other medicines, Pluvicto, Leqvio, among others, could be significant medicines in China over time.
Operator
Your next question comes from the line of Andrew Baum from Citi.
Andrew Baum -- Citi -- Analyst
 A question on the IRA impact on catastrophic coverage and the burden on PBMs and managed care. A significant part of Kisqali is through the Medicare channel. Ibrance seems to be available at a much lower price post genericization. To what extent -- to what extent, excuse me, do you see deflation of the price of Kisqali within the Medicare segment because there'll be preauthorization step [Inaudible] within Medicare prior to gaining access to Kisqali? And do you see any risk of spillover of that, assuming that thesis is correct, to the commercial book of business?
Vas Narasimhan -- Chief Executive Officer
That's a good question, Andrew. I think in general I'd say we're doing a lot of scenario planning on how the IRA could impact various brands. And I think certainly on our minds is how the increased exposure of PBMs in the catastrophic, how that will get transferred or translated into actions against some of our medicines. I think the key for us to differentiate versus a generic in a class like in the CDK4/6, will be having a broader indication -- set of indications relative to the existing medicine.
So I think that's going to be absolutely critical for us in this class to hopefully have the opportunity to expand into, as I mentioned earlier, Stage 2a, Stage 2b, and Stage 3 patients. Otherwise, I think there could certainly be spillover from -- in the metastatic setting if there aren't broad indications for the other 2 players. So we'll have to see how this plays out. I would also say, in general, in some of these cancer classes, such as the CDK4/6, you do see contracting and you do see the opportunity for commercial insurers to get rebates from branded products.
So that would be the, I think, tension there in the system, is they would have to give up their commercial rebates to potentially utilize the generic. So we'll have to see ultimately how all of this plays out. Thank you, Andrew.
Operator
Your next question comes fro